comparemela.com

Latest Breaking News On - Mv capital management inc - Page 6 : comparemela.com

Eagle Asset Management Inc Boosts Position in DexCom, Inc (NASDAQ:DXCM)

Eagle Asset Management Inc. grew its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,756,216 shares of the medical device company’s stock after acquiring an additional 310,728 shares during the […]

Vanguard Communication Services ETF (NYSEARCA:VOX) Shares Sold by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC trimmed its holdings in Vanguard Communication Services ETF (NYSEARCA:VOX – Free Report) by 3.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 15,232 shares of the company’s stock after selling 500 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Vanguard Communication Services […]

Redburn Atlantic Initiates Coverage on DexCom (NASDAQ:DXCM)

Analysts at Redburn Atlantic initiated coverage on shares of DexCom (NASDAQ:DXCM – Get Free Report) in a note issued to investors on Thursday, Marketbeat reports. The brokerage set a “neutral” rating and a $130.00 price target on the medical device company’s stock. Redburn Atlantic’s price objective would suggest a potential upside of 9.46% from the […]

Owens Corning (NYSE:OC) Insider Sells $1,726,066 00 in Stock

Owens Corning (NYSE:OC – Get Free Report) insider Marcio A. Sandri sold 9,697 shares of the stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $178.00, for a total transaction of $1,726,066.00. Following the sale, the insider now owns 62,895 shares in the company, valued at $11,195,310. […]

Agilent Technologies (NYSE:A) Given New $125 00 Price Target at Barclays

Agilent Technologies (NYSE:A – Free Report) had its price objective reduced by Barclays from $135.00 to $125.00 in a report released on Friday, Benzinga reports. They currently have an underweight rating on the medical research company’s stock. Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus cut their price target […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.